Journal
MODERN RHEUMATOLOGY
Volume 22, Issue 2, Pages 298-302Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1007/s10165-011-0497-5
Keywords
Behcet's disease; IL-6; Tocilizumab
Categories
Funding
- National Institute of Biomedical Innovation
- Chugai Pharmaceutical Co., Ltd.
Ask authors/readers for more resources
A 47-year-old female patient with Beh double dagger et's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Beh double dagger et's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available